| pubmed-article:19704171 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19704171 | lifeskim:mentions | umls-concept:C0369332 | lld:lifeskim |
| pubmed-article:19704171 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19704171 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19704171 | lifeskim:mentions | umls-concept:C0209738 | lld:lifeskim |
| pubmed-article:19704171 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:19704171 | lifeskim:mentions | umls-concept:C0439659 | lld:lifeskim |
| pubmed-article:19704171 | lifeskim:mentions | umls-concept:C1442488 | lld:lifeskim |
| pubmed-article:19704171 | lifeskim:mentions | umls-concept:C0549178 | lld:lifeskim |
| pubmed-article:19704171 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:19704171 | lifeskim:mentions | umls-concept:C0549193 | lld:lifeskim |
| pubmed-article:19704171 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:19704171 | pubmed:dateCreated | 2009-8-25 | lld:pubmed |
| pubmed-article:19704171 | pubmed:abstractText | This study aimed to identify the baseline hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT) levels and on-treatment HBV DNA levels for favourable outcome in patients receiving 5-year lamivudine. | lld:pubmed |
| pubmed-article:19704171 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19704171 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704171 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19704171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704171 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704171 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19704171 | pubmed:issn | 1359-6535 | lld:pubmed |
| pubmed-article:19704171 | pubmed:author | pubmed-author:YuenMan-FungM... | lld:pubmed |
| pubmed-article:19704171 | pubmed:author | pubmed-author:YuenJohn... | lld:pubmed |
| pubmed-article:19704171 | pubmed:author | pubmed-author:LaiChing-Lung... | lld:pubmed |
| pubmed-article:19704171 | pubmed:author | pubmed-author:WongDanny... | lld:pubmed |
| pubmed-article:19704171 | pubmed:author | pubmed-author:FungJamesJ | lld:pubmed |
| pubmed-article:19704171 | pubmed:author | pubmed-author:SetoWai-KayWK | lld:pubmed |
| pubmed-article:19704171 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19704171 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:19704171 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19704171 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19704171 | pubmed:pagination | 679-85 | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:meshHeading | pubmed-meshheading:19704171... | lld:pubmed |
| pubmed-article:19704171 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19704171 | pubmed:articleTitle | Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. | lld:pubmed |
| pubmed-article:19704171 | pubmed:affiliation | Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong. mfyuen@hkucc.hku.hk | lld:pubmed |
| pubmed-article:19704171 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19704171 | pubmed:publicationType | Clinical Trial | lld:pubmed |
